Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27494378 | 0.86 | SIGMAR1 (0.75) | SIGMAR1OPRM1OPRK1CHRNA7 | |
| SCHEMBL5142329 | 0.81 | OPRM1 (0.61) | SIGMAR1OPRM1OPRK1CHRNA7MEN1 | |
| SCHEMBL10340117 | 0.80 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRK1ALDH1A1MEN1 | |
| SCHEMBL7344793 | 0.80 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRK1ALDH1A1MEN1 | |
| SCHEMBL11087924 | 0.79 | EPHX2 (0.64) | SIGMAR1EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL6385132 | 0.79 | EPHX2 (0.64) | SIGMAR1EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL28944413 | 0.79 | EPHX2 (0.56) | SIGMAR1EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL14368746 | 0.79 | EPHX2 (0.56) | SIGMAR1EPHX2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7345768 | 0.78 | MCOLN2 (0.63) | SIGMAR1OPRM1OPRK1CHRNA7 | |
| Hydrochloric Acid SCHEMBL7345773 | 0.78 | MCOLN2 (0.63) | SIGMAR1OPRM1OPRK1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263178-B2 | Pharmaceutical compositions and methods | POP TEST ONCOLOGY LLC (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230142627-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-0380063-B1 | 1,2-CYCLOHEXYLAMINOARYL AMIDES USEFUL AS ANALGESIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142627-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | NR3C2, NR3C1, MC2R | SIGMAR1 2488/4885EPHX2 1674/4885OPRM1 1324/4885 |
| US-12263178-B2 | Pharmaceutical compositions and methods | NR3C2, NR3C1, MC2R | SIGMAR1 2488/4885EPHX2 1674/4885OPRM1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.